Warning: The NCBI web site requires JavaScript to function. more...
Advances in quantitative magnetic resonance imaging-based biomarkers for Alzheimer disease.
Dickerson BC.
Alzheimers Res Ther. 2010 Jul 6;2(4):21.
Related citations
Applications of neuroimaging to disease-modification trials in Alzheimer's disease.
Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS; Alzheimer's Disease Neuroimaging Initiative.
Behav Neurol. 2009;21(1):129-36. Review.
Brain imaging in drug R&D.
Zijdenbos AP, Lerch JP, Bedell BJ, Evans AC.
Biomarkers. 2005 Nov;10 Suppl 1:S58-68. Review.
The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE.
Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. Epub 2010 Feb 26. Review.
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease.
Kantarci K, Jack CR Jr.
NeuroRx. 2004 Apr;1(2):196-205. Review.
Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM, Labonte MJ, Lenz HJ.
Cancer J. 2010 May-Jun;16(3):262-72. Review.
Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD, Flickinger JC, Larson D.
Oncologist. 1997;2(1):59-61.
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.
Alzheimers Dement. 2008 Jan;4(1):38-48. Epub 2007 Dec 21. Review.
Image-based biomarkers in clinical practice.
Bayouth JE, Casavant TL, Graham MM, Sonka M, Muruganandham M, Buatti JM.
Semin Radiat Oncol. 2011 Apr;21(2):157-66. Review.
The role of biomarkers in clinical trials for Alzheimer disease.
Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E.
Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):6-15. Review.
Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease.
Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF.
Brain Res Rev. 2008 Jun;58(1):209-25. Epub 2008 Apr 9. Review.
Magnetic resonance approaches to brain aging and Alzheimer disease-associated neuropathology.
Anderson VC, Litvack ZN, Kaye JA.
Top Magn Reson Imaging. 2005 Dec;16(6):439-52. Review.
Multimodal classification of Alzheimer's disease and mild cognitive impairment.
Zhang D, Wang Y, Zhou L, Yuan H, Shen D; Alzheimer's Disease Neuroimaging Initiative.
Neuroimage. 2011 Apr 1;55(3):856-67. Epub 2011 Jan 12.
Magnetic resonance imaging in clinical trials.
Ciumas C, Montavont A, Ryvlin P.
Curr Opin Neurol. 2008 Aug;21(4):431-6. Review.
The opportunities and challenges of developing imaging biomarkers to study lung function and disease.
Schuster DP.
Am J Respir Crit Care Med. 2007 Aug 1;176(3):224-30. Epub 2007 May 3. Review.
Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers.
Hampel H, Broich K.
J Nutr Health Aging. 2009 Apr;13(4):373-5.
Assessment of the progression of Parkinson's disease: a metabolic network approach.
Eckert T, Tang C, Eidelberg D.
Lancet Neurol. 2007 Oct;6(10):926-32. Review.
The role of MRI and PET/SPECT in Alzheimer's disease.
Coimbra A, Williams DS, Hostetler ED.
Curr Top Med Chem. 2006;6(6):629-47. Review.
Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis.
Zijdenbos AP, Forghani R, Evans AC.
IEEE Trans Med Imaging. 2002 Oct;21(10):1280-91.
Biomarkers for chronic pain and analgesia. Part 2: how, where, and what to look for using functional imaging.
Borsook D, Becerra L, Hargreaves R.
Discov Med. 2011 Mar;11(58):209-19. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on